DFTX
NASDAQ · Pharmaceuticals
Definium Therapeutics Inc
$17.79
-0.31 (-1.71%)
Financial Highlights (FY 2025)
Revenue
685.27M
Net Income
136.42M
Gross Margin
43.5%
Profit Margin
19.9%
Rev Growth
-7.8%
D/E Ratio
0.71
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 43.5% | 43.5% | 43.5% |
| Operating Margin | 18.5% | 19.4% | 21.4% |
| Profit Margin | 19.9% | 19.0% | 15.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 685.27M | 628.04M | 535.94M |
| Gross Profit | 298.08M | 273.18M | 233.12M |
| Operating Income | 126.54M | 121.81M | 114.63M |
| Net Income | 136.42M | 119.21M | 84.03M |
| Gross Margin | 43.5% | 43.5% | 43.5% |
| Operating Margin | 18.5% | 19.4% | 21.4% |
| Profit Margin | 19.9% | 19.0% | 15.7% |
| Rev Growth | -7.8% | +7.1% | -9.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 422.39M | 382.18M | 352.68M |
| Total Equity | 596.50M | 672.97M | 673.84M |
| D/E Ratio | 0.71 | 0.57 | 0.52 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 222.00M | 198.31M | 161.40M |
| Free Cash Flow | 100.39M | 95.21M | 82.42M |